<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12098544</article-id><article-id pub-id-type="doi">10.3389/fimmu.2025.1596963</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>The effects of postponing BCG vaccination on the risk of BCG-related complications among patients with severe combined immunodeficiency disease in Saudi Arabia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Aldhaheri</surname><given-names>Amal</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/3010545/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Alyabes</surname><given-names>Ohoud</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Aljumaah</surname><given-names>Suliman</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/></contrib><contrib contrib-type="author"><name><surname>Alhuthil</surname><given-names>Raghad</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1852518/overview"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/></contrib><contrib contrib-type="author"><name><surname>Alonazi</surname><given-names>Raghad</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Alamoudi</surname><given-names>Shefa</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Alsuhaibani</surname><given-names>Mohammed</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Alghamdi</surname><given-names>Salem</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Albanyan</surname><given-names>Esam A.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Al-Hajjar</surname><given-names>Sami</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2837789/overview"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Mohammed</surname><given-names>Reem</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1525129/overview"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Arnaout</surname><given-names>Rand</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/492340/overview"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Albuhairi</surname><given-names>Sultan</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Alrumayyan</surname><given-names>Nora</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Al-Saud</surname><given-names>Bandar</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/420338/overview"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Al-Mousa</surname><given-names>Hamoud</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/383810/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Department of Pediatrics, Pediatrics Infectious Diseases, Medical College, King Abdulaziz University</institution>, <addr-line>Jeddah</addr-line>, <country>Saudi Arabia</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Section of Infectious Diseases, Department of Pediatrics, King Faisal Specialist Hospital and Research Center</institution>, <addr-line>Riyadh</addr-line>, <country>Saudi Arabia</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>College of Medicine, Alfaisal University</institution>, <addr-line>Riyadh</addr-line>, <country>Saudi Arabia</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Section of Pediatric Allergy and Immunology, Department of Pediatrics, King Faisal Specialist Hospital and Research Center</institution>, <addr-line>Riyadh</addr-line>, <country>Saudi Arabia</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Waleed Al-Herz, Kuwait University, Kuwait</p></fn><fn fn-type="edited-by"><p>Reviewed by: Luis Ignacio Gonzalez-Granado, University Hospital October 12, Spain</p><p>Safa Baris, Marmara University, T&#x000fc;rkiye</p></fn><corresp id="fn001">*Correspondence: Hamoud Al-Mousa, <email xlink:href="mailto:hamoudalmousa@kfshrc.edu.sa">hamoudalmousa@kfshrc.edu.sa</email>; Ohoud Alyabes, <email xlink:href="mailto:oyabes@kfshrc.edu.sa">oyabes@kfshrc.edu.sa</email>
</corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>1596963</elocation-id><history><date date-type="received"><day>20</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>18</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Aldhaheri, Alyabes, Aljumaah, Alhuthil, Alonazi, Alamoudi, Alsuhaibani, Alghamdi, Albanyan, Al-Hajjar, Mohammed, Arnaout, Albuhairi, Alrumayyan, Al-Saud and Al-Mousa</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Aldhaheri, Alyabes, Aljumaah, Alhuthil, Alonazi, Alamoudi, Alsuhaibani, Alghamdi, Albanyan, Al-Hajjar, Mohammed, Arnaout, Albuhairi, Alrumayyan, Al-Saud and Al-Mousa</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>The Bacillus Calmette&#x02013;Gu&#x000e9;rin (BCG) vaccine is widely used to prevent tuberculosis but is associated with significant complications in patients with severe combined immunodeficiency (SCID). Considering the high incidence of SCID in Saudi Arabia, the Ministry of Health revised its national vaccination schedule in 2019, postponing BCG administration from birth to 6 months of age, aiming to enable time for the diagnosis of primary immunodeficiency diseases before vaccination. This study evaluated the consequences of this policy change on the incidence of BCG-related complications in SCID patients.</p></sec><sec><title>Methods</title><p>This retrospective study included 178 SCID patients diagnosed at King Faisal Specialist Hospital and Research Center, Riyadh, between 2015 and 2023. Patients were divided into two cohorts: Era 1 (2015&#x02013;2019), when BCG vaccination was administered at birth, and Era 2 (2019&#x02013;2023), when BCG vaccination was administered at 6 months of age. Data on demographics, clinical presentations, BCG-related complications, genetic testing, treatment, and outcomes were analyzed.</p></sec><sec><title>Results</title><p>A total of 49 SCID patients developed BCGitis, of which 65.3% experienced disseminated disease. The incidence of BCG-related complications dropped significantly after the policy change, from 46.1% in Era 1 to 2.6% in Era 2. Patients required stem cell transplantation and a median of 17.6 months of anti-mycobacterial therapy. The crude mortality rate was high (36.7%; 18/49), with 66.7% (12/18) of these fatalities linked to disseminated BCGitis.</p></sec><sec><title>Conclusions</title><p>Postponing BCG vaccination to 6 months of age significantly decreases the incidence of BCG-related complications in SCID patients and highlights the importance of tailoring vaccination schedules for high-risk populations. Early newborn screening and timely diagnosis of immunodeficiencies are essential to further minimize complications. The revised vaccination policy of Saudi Arabia provides a model for optimizing immunization strategies in regions with a high prevalence of inborn errors of immunity.</p></sec></abstract><kwd-group><kwd>Bacillus Calmette Guerin</kwd><kwd>severe combined immunodeficiency disease</kwd><kwd>vaccination</kwd><kwd>Saudi Arabia</kwd><kwd>tuberculosis</kwd><kwd>inborn errors of immunity</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that no financial support was received for the research and/or publication of this article.</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="3"/><equation-count count="0"/><ref-count count="33"/><page-count count="8"/><word-count count="3642"/></counts><custom-meta-group><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Primary Immunodeficiencies</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>Tuberculosis (TB) is a global health issue, and Saudi Arabia is no exception, with a reported incidence of 14 cases per 100,000 people (<xref rid="B1" ref-type="bibr">1</xref>). Since 1912, the only available vaccine for TB has been the Bacillus Calmette Guerin (BCG) vaccine, which contains live attenuated <italic>Mycobacterium bovis</italic> (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>). The BCG vaccine has been used to combat TB and is considered one of the most extensively used vaccinations in the world today. Since the 1960s, it has been routinely administered in most nations, mostly to newborns through national childhood vaccination programs. BCG vaccination protects against meningitis and disseminated TB but does not prevent primary infection or, more crucially, the reactivation of latent pulmonary infection, which is the major source of community transmission. The BCG vaccine was first introduced to Saudi Arabia in 1964 and was initially designated to high-risk populations but was then expanded to all newborns in 1970 (<xref rid="B4" ref-type="bibr">4</xref>). However, the vaccine has been associated with significant adverse effects, including local ulceration at the vaccine site, regional lymphadenitis, osteomyelitis, and disseminated disease with an overall rate of 0.5&#x02013;100 cases per 1,000 vaccinations (<xref rid="B5" ref-type="bibr">5</xref>). In Saudi Arabia, the BCG vaccine is part of the nationwide vaccination schedule and is administered to all infants at birth. An increased prevalence of BCG-related lymphadenitis (0&#x02013;10.4 cases per 1,000 vaccinations) has been observed since the Danish strain (SSI 1331) started to be used in November 2005 (<xref rid="B4" ref-type="bibr">4</xref>).</p><p>Severe combined immunodeficiency (SCID) is a group of hereditary diseases defined by inhibited T lymphocyte differentiation, which is sometimes coupled with abnormal development of other lymphocyte lineages, such as B or natural killer (NK) cells (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>). Early-onset infections, interstitial pneumonitis, oral candidiasis, and persistent diarrhea with growth retardation are all common clinical presentations. SCID is characterized by a high level of genetic and clinical heterogeneity, as more than 14 genetic defects have been identified and can be distinguished according to cellular phenotype, inheritance pattern, and the responsible genes (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>). Live attenuated vaccinations are strictly contraindicated in SCID patients. However, because the BCG vaccine is often administered at a very young age, SCID patients are immunized before being diagnosed with SCID. SCID patients have a very high incidence of complications due to BCG vaccination, exhibiting higher rates of morbidity and mortality. In a comprehensive study investigating the effects of BCG in 349 SCID patients who were vaccinated prior to diagnosis, 51% experienced complications, of which 34% were disseminated, and 17% were localized. T cell counts of &#x0003c;250/&#x000b5;L and BCG vaccination within the first month of life were identified as risk factors for BCG disease development. Among the 160 patients treated with anti-mycobacterial treatment for symptomatic BCG infection, 46 BCG-associated fatalities were documented (<xref rid="B10" ref-type="bibr">10</xref>).</p><p>Consanguineous marriages are prevalent in Saudi Arabia, with a total rate of 60% (<xref rid="B11" ref-type="bibr">11</xref>). Most monogenic SCID causes are autosomal recessive and are thus likely to be more frequent in regions with high rates of consanguineous marriages (<xref rid="B12" ref-type="bibr">12</xref>). Our previous pilot T cell receptor excision circle-based newborn screening project revealed a high incidence of SCID among the Saudi population (1/2,906 live births), which is 20-fold higher than the incidence reported in the USA (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>). For this reason, in August 2019, the Ministry of Health in Saudi Arabia postponed BCG vaccination to 6 months of age, thereby enabling more time for potential diagnoses of primary immunodeficiency diseases. However, limited studies have evaluated the effects of administering the BCG vaccine at birth compared to later ages (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>). The aim of this study was to assess the effects of delaying BCG vaccination to the age of 6 months on the risk of developing BCG-related complications among SCID patients.</p></sec><sec id="s2"><label>2</label><title>Methods</title><sec id="s2_1"><label>2.1</label><title>Study design and population</title><p>This was a retrospective study that reviewed all SCID patients who were diagnosed at the King Faisal Specialist Hospital and Research Center (KFSH-RC) in Riyadh, Saudi Arabia, over 8 years (from January 2015 to January 2023). The study compared the incidence of BCG-related complications in SCID patients between two periods (1): Era 1, from January 2015 to July 2019 (prior to the schedule change), during which all newborns received BCG vaccination at birth, and (2) Era 2, from August 2019 to January 2023 (after the updated national vaccination schedule), during which BCG vaccination was administered to all infants at the age of 6 months (<xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1</bold>
</xref>). This study included all SCID patients who had documented BCG-related complications following BCG vaccination and excluded patients who did not receive the BCG vaccine. This study was approved by the Institutional Review Board at KFSH-RC (reference number: 2231217, approval date: July 12, 2023).</p><fig position="float" id="f1"><label>Figure&#x000a0;1</label><caption><p>Summary of the study cohort. *A significant decrease in the incidence of Bacillus Calmette&#x02013;Gu&#x000e9;rin infections (BCGitis) was noted in Era 2 (2.6%) compared with Era 1 (46.1%; <italic>p</italic> &#x0003c; 0.001).</p></caption><graphic xlink:href="fimmu-16-1596963-g001" position="float"/></fig></sec><sec id="s2_2"><label>2.2</label><title>Definitions</title><p>SCID was defined according to the diagnostic criteria of the Primary Immune Deficiency Treatment Consortium (<xref rid="B17" ref-type="bibr">17</xref>). BCG-related disease was defined as local, regional, or disseminated using the pediatric criteria developed by Hesseling and colleagues (<xref rid="B18" ref-type="bibr">18</xref>). Local BCG disease involves a BCG injection site abscess of &#x0003e; 10 mm or severe BCG scar ulceration. Regional disease involves the enlargement, suppuration, or fistula formation of ipsilateral regional lymph node(s). Disseminated disease involves distant anatomical site(s) beyond the BCG injection site and ipsilateral lymph node(s).</p></sec><sec id="s2_3"><label>2.3</label><title>Data collection and analysis</title><p>Data were collected through electronic chart reviews and entered into the REDCap database (10.8.0, <sup>&#x000a9;</sup> 2021 Vanderbilt University). The extracted data included demographics, medical history, immunological and genetic testing, BCG vaccine-related complications, treatment, antimicrobial susceptibility, stem cell transplantation, and outcomes. Stata 18 (<sup>&#x000a9;</sup> 2025 StataCorp) was used for analyses. Categorical variables were reported as frequency and percentage (%), and continuous variables were reported as medians and interquartile ranges (IQR). Graphs were generated using Microsoft Excel 2016. Univariable analysis was performed using Fisher&#x02019;s exact test. A <italic>p</italic>-value of &#x0003c;0.05 was considered significant.</p></sec></sec><sec sec-type="results" id="s3"><label>3</label><title>Results</title><p>Between January 2015 and January 2023, 179 SCID patients were diagnosed at KFSH-RC. Among the 102 patients in Era 1, 47 (46.1%) suffered from BCG-related disease. Among the 76 patients in Era 2, only 2 (2.6%) suffered from BCG-related complications (p &#x0003c; 0.001) (<xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1</bold>
</xref>).</p><p>Of the 49 BCGitis cases, 22 (44.9%) were boys, and 27 (55.1%) were girls, with a median age of BCG-related clinical presentation of 5 months (IQR: 4&#x02013;7). The overall median time from BCG vaccination to the development of disease manifestations was 5 months (IQR: 4&#x02013;6) (<xref rid="T1" ref-type="table">
<bold>Table&#x000a0;1</bold>
</xref>). BCG-related complications in SCID patients varied in severity: 34.7% exhibited localized or regional disease, whereas 65.3% exhibited disseminated disease (<xref rid="T2" ref-type="table">
<bold>Table&#x000a0;2</bold>
</xref>). SCID (T-, B-, NK+) was the most prevalent phenotype, with <italic>RAG1</italic> and <italic>DCLRE1C</italic> being the most common genetic defects (<xref rid="T1" ref-type="table">
<bold>Table&#x000a0;1</bold>
</xref>). The median (interquartile range) for CD3, CD4 and CD8 counts were 116 (17, 1064), 66 (8, 577) and 11 (0, 149)/mm<sup>3</sup> respectively. Diagnoses were made mainly through culture (61.2%), gastric aspirate (8.2%), or clinical diagnosis (30.6%) (<xref rid="T2" ref-type="table">
<bold>Table&#x000a0;2</bold>
</xref>).</p><table-wrap position="float" id="T1"><label>Table&#x000a0;1</label><caption><p>Characteristics of BCGitis cases (n = 49).</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Characteristics</th><th valign="top" align="left" rowspan="1" colspan="1">n (%), Median [IQR]</th></tr></thead><tbody><tr><th valign="top" colspan="2" align="left" rowspan="1">Gender</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Male</td><td valign="top" align="left" rowspan="1" colspan="1">22 (44.9)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Female</td><td valign="top" align="left" rowspan="1" colspan="1">27 (55.1)</td></tr><tr><th valign="top" colspan="2" align="left" rowspan="1">Age at BCG vaccine</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">At birth</td><td valign="top" align="left" rowspan="1" colspan="1">47 (95.9)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">At 6 months</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4.1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age at SCID diagnosis (months)</td><td valign="top" align="left" rowspan="1" colspan="1">5 [4, 7]</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BCGitis presentation age (months)</td><td valign="top" align="left" rowspan="1" colspan="1">5 [4, 6]</td></tr><tr><th valign="top" colspan="2" align="left" rowspan="1">SCID Type</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">T&#x02212;, B&#x02212;, NK+</td><td valign="top" align="left" rowspan="1" colspan="1">23 (46.9)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">T&#x02212;, B+, NK+</td><td valign="top" align="left" rowspan="1" colspan="1">3 (6.1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">T&#x02212;, B+, NK&#x02212;</td><td valign="top" align="left" rowspan="1" colspan="1">6 (12.2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">T&#x02212;, B&#x02212;, NK&#x02212;</td><td valign="top" align="left" rowspan="1" colspan="1">3 (6.1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">T+, B&#x02212;, NK+ (Omenn)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (22.5)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">T+, B&#x02212;, NK&#x02212; (Omenn)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">T+,B+,NK+ (Omenn)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CD8 deficiency</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2.0)</td></tr><tr><th valign="top" colspan="2" align="left" rowspan="1">SCID Gene Mentioned (n = 40)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>ADA</italic> deficiency</td><td valign="top" align="left" rowspan="1" colspan="1">3 (7.5)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>CD3E</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2.5)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>DCLRE1C</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">6 (15)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>DNA</italic> ligase 1 deficiency</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2.5)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>IL2RG</italic> chain mutation</td><td valign="top" align="left" rowspan="1" colspan="1">2 (5.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>JAK3</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">5 (12.5)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>LAT</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2.5)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>NHEJ1</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2.5)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>PNP</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">2 (5.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>RAG1</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">15 (37.5)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>RAG2</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">2 (5.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>ZAP-70</italic> deficiencies</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2.5)</td></tr></tbody></table><table-wrap-foot><fn><p>IQR, interquartile range; BCGitis, Bacille Calmette&#x02013;Gu&#x000e9;rin infection; BCG, Bacille Calmette&#x02013;Gu&#x000e9;rin vaccine; SCID, severe combined immunodeficiency; NK, natural killer cells; <italic>ADA</italic>, adenosine deaminase; <italic>CD3E</italic>, CD3 epsilon subunit; <italic>DCLRE1C</italic>, DNA cross-link repair 1C; <italic>IL2RG</italic>, interleukin-2 receptor subunit gamma; <italic>JAK3</italic>, Janus kinase 3; <italic>LAT</italic>, linker for activation of T cells; <italic>NHEJ1</italic>, non-homologous end-joining factor 1; <italic>PNP</italic>, purine nucleoside phosphorylase; <italic>RAG1</italic>, recombination activating gene 1; <italic>RAG2</italic>, recombination activating gene 2; <italic>ZAP-70</italic>, zeta-associated protein 70.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table&#x000a0;2</label><caption><p>Management and outcomes of BCGitis (n = 49).</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Investigations</th><th valign="top" align="left" rowspan="1" colspan="1">n (%), Median [IQR]</th></tr></thead><tbody><tr><th valign="top" colspan="2" align="left" rowspan="1">BCGitis diagnosis</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Culture</td><td valign="bottom" align="left" rowspan="1" colspan="1">30 (61.2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AFP gastric Aspiration</td><td valign="bottom" align="left" rowspan="1" colspan="1">4 (8.2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Clinical</td><td valign="bottom" align="left" rowspan="1" colspan="1">15 (30.6)</td></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">HSCT</th><th valign="middle" align="left" rowspan="1" colspan="1">44 (89.8)</th></tr><tr><td valign="top" colspan="2" align="left" rowspan="1">Type of HSCT (n = 44)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Full Matched</td><td valign="middle" align="left" rowspan="1" colspan="1">26 (59.1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Haploidentical</td><td valign="middle" align="left" rowspan="1" colspan="1">12 (27.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Umbilical Cord Transplant</td><td valign="middle" align="left" rowspan="1" colspan="1">6 (13.6)</td></tr><tr><th valign="bottom" colspan="2" align="left" rowspan="1">Target treatment</th></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Clarithromycin</td><td valign="bottom" align="left" rowspan="1" colspan="1">46 (93.9)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Ethambutol</td><td valign="bottom" align="left" rowspan="1" colspan="1">38 (77.6)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Rifampicin</td><td valign="bottom" align="left" rowspan="1" colspan="1">30 (61.2)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Ciprofloxacin</td><td valign="bottom" align="left" rowspan="1" colspan="1">22 (44.9)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Levofloxacin</td><td valign="bottom" align="left" rowspan="1" colspan="1">20 (40.8)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Isoniazid</td><td valign="bottom" align="left" rowspan="1" colspan="1">19 (38.8)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Amikacin</td><td valign="bottom" align="left" rowspan="1" colspan="1">13 (26.5)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Cycloserine</td><td valign="bottom" align="left" rowspan="1" colspan="1">10 (20.4)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Moxifloxacin</td><td valign="bottom" align="left" rowspan="1" colspan="1">6 (12.2)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Linezolid</td><td valign="bottom" align="left" rowspan="1" colspan="1">2 (4.1)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Ceftazidime-Avibactium</td><td valign="bottom" align="left" rowspan="1" colspan="1">1 (2.0)</td></tr><tr><th valign="top" colspan="2" align="left" rowspan="1">Treatment status</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Completed</td><td valign="bottom" align="left" rowspan="1" colspan="1">30 (61.2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Died during treatment</td><td valign="bottom" align="left" rowspan="1" colspan="1">17 (34.7)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stopped by the family</td><td valign="bottom" align="left" rowspan="1" colspan="1">1 (2.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ongoing</td><td valign="bottom" align="left" rowspan="1" colspan="1">1 (2.0)</td></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Treatment duration (months) (n=30)</th><th valign="middle" align="left" rowspan="1" colspan="1">17.6 [13.5, 24.2]</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Regional/Local disease</td><td valign="bottom" align="left" rowspan="1" colspan="1">17 (34.7)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Regional disease</td><td valign="bottom" align="left" rowspan="1" colspan="1">16 (94.1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Local BCG disease</td><td valign="bottom" align="left" rowspan="1" colspan="1">1 (5.9)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Disseminated disease</td><td valign="bottom" align="left" rowspan="1" colspan="1">32 (65.3)</td></tr><tr><th valign="top" colspan="2" align="left" rowspan="1">Dissemination site (n = 32)*</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Liver/spleen</td><td valign="bottom" align="left" rowspan="1" colspan="1">8 (25.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Bone</td><td valign="bottom" align="left" rowspan="1" colspan="1">8 (25.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lymph nodes</td><td valign="bottom" align="left" rowspan="1" colspan="1">12 (37.5)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Skin</td><td valign="bottom" align="left" rowspan="1" colspan="1">10 (31.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Muscles</td><td valign="bottom" align="left" rowspan="1" colspan="1">1 (3.1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lung(s)</td><td valign="bottom" align="left" rowspan="1" colspan="1">10 (31.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Intrabdominal collection</td><td valign="bottom" align="left" rowspan="1" colspan="1">1 (3.1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Crude mortality</td><td valign="bottom" align="left" rowspan="1" colspan="1">18/49 (36.7)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Contributing causes of mortality<break/>Invasive fungal intracranial infection<break/>Lack of full match donor<break/>Pneumonia and septic shock<break/>Post HSCT veno-occlusive disease<break/>Measles</td><td valign="bottom" align="left" rowspan="1" colspan="1">1<break/>2<break/>10<break/>1<break/>1</td></tr></tbody></table><table-wrap-foot><fn><p>*Twelve patients had more than one dissemination site.</p></fn><fn><p>HSCT, hematopoietic stem cell transplantation; BCG, Bacillus Calmette&#x02013;Gu&#x000e9;rin; AFP, acid-fast bacilli.</p></fn></table-wrap-foot></table-wrap><p>Treatment included hematopoietic stem cell transplantation and anti-mycobacterial therapy. Hematopoietic stem cell transplantation was performed in 89.8% of patients. The most commonly used anti-TB treatments were clarithromycin (93.9%), ethambutol (77.6%), and rifampicin (61.2%). Treatment durations were prolonged, with a median of 17.6 months (IQR: 13.5&#x02013;24.2) (<xref rid="T2" ref-type="table">
<bold>Table&#x000a0;2</bold>
</xref>). All culture isolates demonstrated 100% sensitivity to cycloserine, clarithromycin, ciprofloxacin, moxifloxacin, amikacin, ethambutol, ethionamide, and streptomycin. Additionally, 96.0% and 85.2% of the isolates were sensitive to rifampicin and isoniazid, respectively. However, all the isolates were resistant to pyrazinamide. The most commonly used combination of anti-mycobacterial therapy for localized or regional BCG disease was ethambutol, clarithromycin, and ciprofloxacin, administered in 62.5% of patients. In cases of disseminated disease, a four-drug regimen comprising rifampicin, ethambutol, ciprofloxacin, and clarithromycin was employed in 65.6% of patients.</p><p>Among SCID patients with BCG complications, the most prevalent subtype was SCID (T-, B-, NK+), accounting for 50.0% of those with disseminated disease and 41.2% of those with localized or regional disease. This difference was not statistically significant (p = 0.764). However, the SCID subtype T-, B+, NK- was more frequently associated with disseminated disease (18.8%) than localized or regional disease (0.0%), showing a trend toward significance (p = 0.080) (<xref rid="T3" ref-type="table">
<bold>Table&#x000a0;3</bold>
</xref>). The crude mortality rate was 36.7% (18/49). Among these fatalities, 66.7% (12/18) were attributed to disseminated BCGitis (<xref rid="T2" ref-type="table">
<bold>Table&#x000a0;2</bold>
</xref>).</p><table-wrap position="float" id="T3"><label>Table&#x000a0;3</label><caption><p>Relationship between types of severe combined immunodeficiency (SCID) and disseminated Bacillus Calmette&#x02013;Gu&#x000e9;rin infections (BCGitis) (n = 49).</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">SCID Type</th><th valign="top" align="left" rowspan="1" colspan="1">Disseminated Bcgitis (n = 32)</th><th valign="top" align="left" rowspan="1" colspan="1">Regional/local changes <break/>(n = 17)</th><th valign="top" align="left" rowspan="1" colspan="1">
<italic>p</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">T&#x02212;, B&#x02212;, NK+</td><td valign="top" align="left" rowspan="1" colspan="1">16 (50.0)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (41.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.764</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">T&#x02212;, B+, NK+</td><td valign="top" align="left" rowspan="1" colspan="1">2 (6.3)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (5.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">T&#x02212;, B+, NK&#x02212;</td><td valign="top" align="left" rowspan="1" colspan="1">6 (18.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0.0)</td><td valign="top" align="left" rowspan="1" colspan="1">0.080</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">T&#x02212;, B&#x02212;, NK&#x02212;</td><td valign="top" align="left" rowspan="1" colspan="1">2 (6.3)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (5.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">T+, B&#x02212;, NK+ (Omenn)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (18.8)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (29.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0.480</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">T+, B&#x02212;, NK&#x02212; (Omenn)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (5.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0.347</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">T+,B+,NK+ (Omenn)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (5.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0.347</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CD8 deficiency</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (5.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0.347</td></tr></tbody></table></table-wrap></sec><sec sec-type="discussion" id="s4"><label>4</label><title>Discussion</title><p>The prevalence of BCG complications in the general population varies significantly depending on the nation and vaccine strain used. However, the rates of localized and disseminated complications are estimated at 1 in 2,500 and 1 in 100,000 vaccinations, respectively (<xref rid="B19" ref-type="bibr">19</xref>). All SCID patients with varying underlying genetic abnormalities have a defective adaptive immune response, which impairs mycobacterial infection control. As a result, the frequency of BCG-related complications in SCID patients is greater than that in the general population (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B20" ref-type="bibr">20</xref>&#x02013;<xref rid="B23" ref-type="bibr">23</xref>). The combined experience of 28 centers in 17 countries revealed that one out of every two BCG-vaccinated SCID patients develops BCG-related manifestations, with two-thirds developing disseminated complications (representing a 33,000-fold higher risk compared to the general population) and the other one-third developing localized complications (representing a 400-fold higher risk compared to the general population). Two factors are strongly associated with the higher occurrence of BCG complications: the total number of T cells at the time of SCID diagnosis and age at the time of BCG vaccination. SCID patients who were vaccinated within the first month of life had a significantly greater risk of BCG-related complications, which was associated with an increased likelihood of vaccine-related mortality (<xref rid="B10" ref-type="bibr">10</xref>).</p><p>Consanguineous marriages are a strongly ingrained custom in Middle Eastern and North African nations, contributing to an increase in the occurrence of autosomal recessive disorders such as inborn errors of immunity (<xref rid="B12" ref-type="bibr">12</xref>). A newborn screening pilot study in Saudi Arabia revealed a high prevalence of SCID (1/2,906 live births) (<xref rid="B13" ref-type="bibr">13</xref>). We previously reported that disseminated <italic>M. bovis</italic> was found in 49 out of 114 (43%) SCID patients receiving the BCG vaccine at birth at KFSH-RC between 2010 and 2013 (<xref rid="B24" ref-type="bibr">24</xref>). In Saudi Arabia, the BCG vaccine has traditionally been administered to newborns at birth. However, recent guidelines from the Saudi Ministry of Health recommend postponing BCG vaccination until the age of 6 months, aiming to enhance vaccine safety and efficacy. This policy shift in Saudi Arabia has significantly decreased vaccine-related complications, particularly in SCID patients. Our study demonstrates a significant decrease in the incidence of BCGitis, from 46.1% before the policy change to 2.6% post-implementation. This suggests a strong association between the timing of BCG vaccination and adverse outcomes in vulnerable populations. Such findings emphasize the importance of tailoring immunization schedules to align with the safety and needs of high-risk groups, particularly for countries with a high incidence of inborn errors of immunity. Our study also underscores the importance of continuously evaluating vaccination policies to ensure optimal protection while minimizing risks.</p><p>Delaying BCG vaccination to the age of 6 months can have both potential benefits and risks in terms of TB prevention in the general population. Delaying vaccination may leave infants unprotected during the critical first months of life, especially in regions with high TB incidence. In regions with low TB incidence, delaying BCG vaccination may have negligible effects on overall TB rates (<xref rid="B15" ref-type="bibr">15</xref>). Conversely, in regions with widespread TB, delaying vaccination could lead to an increase in TB cases among unvaccinated infants, affecting community-level TB control efforts. However, studies suggest that administering the BCG vaccine at an older age may lead to a more robust immune response, potentially improving its efficacy in preventing TB. This could be due to the enhanced maturity of an infant&#x02019;s immune system at 6 months compared to the neonatal period (<xref rid="B16" ref-type="bibr">16</xref>). Delaying BCG vaccination to 6 months of age in countries with a high incidence of inborn errors of immunity can significantly decrease vaccine-related complications but must be carefully weighed against the risk of TB exposure in infancy. In such settings, tailoring vaccination policies to the local epidemiology of TB and incidence of inborn errors of immunity is critical for minimizing risks while ensuring effective TB prevention.</p><p>Previous studies have shown that the risk of BCG-related complications is independent of the SCID subtype (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B23" ref-type="bibr">23</xref>). In our cohort, the T-, B+, NK- SCID phenotype showed a borderline association with disseminated disease (p = 0.080). This might be related to a lack of NK cells, which act at the interface of innate and adaptive immunity to control infections and shape immune responses and hence play a significant role in controlling mycobacterial infections (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>). In our study, only two patients (2.6%) developed BCG-related complications after postponed vaccination; both cases were diagnosed with SCID relatively late, i.e., at 10 and 22 months of age. These patients presented with BCGitis at 12 and 22 months, respectively. The first patient had <italic>JAK3</italic> SCID and developed regional BCGitis in the ipsilateral lymph nodes, whereas the second patient had <italic>PNP</italic> SCID and developed disseminated BCGitis, which resulted in death. These two cases underscore the critical importance of early immunodeficiency screening to optimize vaccination timing and minimize complications.</p><p>The management of SCID patients and BCG-related complications includes providing immune reconstitution through hematopoietic stem cell transplantation, gene therapy, or enzyme replacement in addition to anti-TB therapy. The antimicrobial therapy used to manage BCG-related complications in patients with inborn errors of immunity (IEI) remains unclear and controversial. This uncertainty stems from the heterogeneity of underlying immune defects, variability in clinical presentation and limited high-quality evidence guiding treatment decisions. In response, several expert guidelines and position papers have been published to provide consensus-based recommendations for the diagnosis and management of these complications (<xref rid="B27" ref-type="bibr">27</xref>&#x02013;<xref rid="B29" ref-type="bibr">29</xref>). We followed the European Society of Immunodeficiency guidelines, which base the recommended regimen intensity on disease severity: two antimicrobials for localized skin manifestations, three for ipsilateral lymphadenitis, and four for disseminated BCGitis. The treatment durations in the cohort of this study varied greatly: 4.3&#x02013;17.1 months for localized and regional BCGitis and 11.5&#x02013;38.3 months for disseminated cases. These durations were influenced by clinical responses, immunological reconstitutions, adverse effects, and therapeutic interactions. The antimicrobial susceptibility studies showed that the BCG strains were 100% sensitive to cycloserine, clarithromycin, ciprofloxacin, moxifloxacin, amikacin, ethambutol, ethionamide, and streptomycin. However, the isoniazid and rifampicin resistance rates were 14.8% and 4.0%, respectively. Isoniazid was underused in our cohort due to concerns regarding the potential development of resistance, as well as the risk of hepatotoxicity and other adverse effects. The universal resistance to pyrazinamide aligns with the known intrinsic resistance of BCG strains. This suggests potential variability in resistance patterns and reinforces the importance of local susceptibility testing to guide treatment choices.</p><p>The crude mortality rate was notably high (36.7%; 18/49), with 66.7% (12/18) of these fatalities linked to disseminated BCGitis. Similarly, Cocchi et&#x000a0;al. reported a mortality rate of 27.8% (10 deaths in 36 patients) (<xref rid="B23" ref-type="bibr">23</xref>). Conversely, Botaro et&#x000a0;al. studied BCG vaccination results in 11 SCID infants in Brazil and reported a higher mortality rate (73%), with 25% of deaths related to BCG vaccination (<xref rid="B21" ref-type="bibr">21</xref>). This significant fatality rate highlights the importance of proactive screening and early management to reduce the risks associated with BCG vaccination in SCID patients. Thus, diagnosing systemic infections caused by BCG vaccination in SCID patients demands a high degree of clinical vigilance and appropriate diagnostic tools, such as mycobacterial cultures, biochemical identification, or polymerase chain reaction. These diagnostic procedures should be initiated promptly in cases of disseminated BCG disease, alongside timely treatment with anti-TB medications and, when feasible, therapies that address the underlying immunodeficiency (<xref rid="B14" ref-type="bibr">14</xref>).</p><p>BCG-related complications are not limited to patients with severe combined immunodeficiency (SCID) but have also been reported in a broader spectrum of inborn errors of immunity (IEI), including combined immunodeficiencies (CID) and phagocytic defects such as chronic granulomatous disease (CGD) and Mendelian susceptibility to mycobacterial disease (MSMD) (<xref rid="B29" ref-type="bibr">29</xref>&#x02013;<xref rid="B33" ref-type="bibr">33</xref>). These conditions, while sometimes diagnosed later in infancy or childhood due to more subtle clinical presentations, still predispose patients to disseminated or severe localized BCG disease if vaccinated early. While delaying BCG vaccination to six months of age&#x02014;as implemented in our study&#x02014;appears to reduce complications in SCID, it may not be sufficient to protect patients with other susceptible IEIs who remain undiagnosed beyond that age. Therefore, similar vaccine-delaying strategies should be investigated in other high-risk IEI populations, particularly in regions with high consanguinity and IEI prevalence. In such settings, a broader discussion is warranted around whether routine BCG vaccination should be postponed even further or potentially withheld altogether until immune competence is confirmed, to mitigate the risk of severe vaccine-related adverse events.</p><sec id="s4_1"><label>4.1</label><title>Limitations</title><p>This study has provided insights into the beneficial effects of postponing BCG vaccination on the risk of BCG-related complications among SCID patients in Saudi Arabia. However, the consequences of postponing BCG vaccination on the risk of TB in the general population must be investigated in future studies.</p></sec></sec><sec sec-type="conclusions" id="s5"><label>5</label><title>Conclusions</title><p>This study demonstrates that postponing BCG vaccination to 6 months of age significantly decreases the incidence of BCGitis in SCID patients, highlighting the importance of adjusting vaccination schedules for high-risk populations. In Saudi Arabia, the policy change to administer the BCG vaccine at 6 months of age allows time for the early diagnosis of immunodeficiencies in infants and may serve as a model for global vaccination strategies in similar contexts. Further research is needed to refine vaccination timing, develop risk stratification methods, and explore alternative immunization approaches to minimize complications in immunocompromised individuals. Additionally, long-term monitoring and earlier screening for immunodeficiencies remain critical for preventing severe vaccine-related complications in this vulnerable group.</p></sec></body><back><fn-group><title>Abbreviations</title><fn fn-type="abbr" id="abbrev1"><p>BCG, Bacillus Calmette&#x02013;Gu&#x000e9;rin; <italic>DCLRE1C</italic>, DNA Cross-Link Repair 1C; IQR, Interquartile range; <italic>JAK3</italic>, Janus Kinase 3; KFSH-RC, King Faisal Specialist Hospital and Research Center; NK, Natural killer; <italic>RAG1</italic>, Recombination Activating Gene 1; SCID, Severe Combined Immunodeficiency; TB, Tuberculosis.</p></fn></fn-group><sec sec-type="data-availability" id="s8"><title>Data availability statement</title><p>The data analyzed in this study is subject to the following licenses/restrictions: Data can be available from the corresponding author upon a reasonable request. Requests to access these datasets should be directed to <email xlink:href="mailto:hamoudalmousa@kfshrc.edu.sa">hamoudalmousa@kfshrc.edu.sa</email>.</p></sec><sec sec-type="ethics-statement" id="s9"><title>Ethics statement</title><p>The studies involving humans were approved by Institutional review board at KFSHRC. The studies were conducted in accordance with the local legislation and institutional requirements. The ethics committee/institutional review board waived the requirement of written informed consent for participation from the participants or the participants&#x02019; legal guardians/next of kin because due to retrospective nature of the study.</p></sec><sec sec-type="author-contributions" id="s10"><title>Author contributions</title><p>AA: Conceptualization, Data curation, Investigation, Methodology, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. OA: Conceptualization, Data curation, Investigation, Methodology, Project administration, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. SuliA: Conceptualization, Data curation, Methodology, Writing &#x02013; review &#x00026; editing, Investigation. RAlh: Data curation, Investigation, Methodology, Writing &#x02013; review &#x00026; editing, Formal Analysis. RAlo: Data curation, Investigation, Methodology, Writing &#x02013; review &#x00026; editing. ShA: Data curation, Investigation, Methodology, Writing &#x02013; review &#x00026; editing. MA: Data curation, Investigation, Methodology, Writing &#x02013; review &#x00026; editing. SaA: Data curation, Investigation, Methodology, Writing &#x02013; review &#x00026; editing. EA: Data curation, Investigation, Methodology, Writing &#x02013; review &#x00026; editing. SA-H: Data curation, Investigation, Methodology, Writing &#x02013; review &#x00026; editing. RM: Data curation, Investigation, Methodology, Writing &#x02013; review &#x00026; editing. RAr: Data curation, Investigation, Methodology, Writing &#x02013; review &#x00026; editing. SultA: Data curation, Investigation, Methodology, Writing &#x02013; review &#x00026; editing. NA: Data curation, Investigation, Methodology, Writing &#x02013; review &#x00026; editing. BA-S: Data curation, Investigation, Methodology, Writing &#x02013; review &#x00026; editing. HA-M: Conceptualization, Data curation, Investigation, Methodology, Project administration, Resources, Supervision, Visualization, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="s12"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s13"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s14"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saati</surname><given-names>AA</given-names></name><name><surname>Khurram</surname><given-names>M</given-names></name><name><surname>Faidah</surname><given-names>H</given-names></name><name><surname>Haseeb</surname><given-names>A</given-names></name><name><surname>Iriti</surname><given-names>M</given-names></name></person-group>. <article-title>A Saudi Arabian public health perspective of tuberculosis</article-title>. <source>Int J Environ Res Public Health</source>. (<year>2021</year>) <volume>18</volume>(<issue>19</issue>):<page-range>1&#x02013;37</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/ijerph181910042</pub-id>
</mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Comstock</surname><given-names>GW</given-names></name></person-group>. <article-title>The International Tuberculosis Campaign: a pioneering venture in mass vaccination and research</article-title>. <source>Clin Infect Dis</source>. (<year>1994</year>) <volume>19</volume>:<page-range>528&#x02013;40</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/clinids/19.3.528</pub-id>
</mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fine</surname><given-names>PE</given-names></name></person-group>. <article-title>Bacille Calmette-Guerin vaccines: a rough guide</article-title>. <source>Clin Infect Dis</source>. (<year>1995</year>) <volume>20</volume>:<page-range>11&#x02013;4</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/clinids/20.1.11</pub-id>
</mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alrabiaah</surname><given-names>AA</given-names></name><name><surname>Alsubaie</surname><given-names>SS</given-names></name><name><surname>Bukhari</surname><given-names>EI</given-names></name><name><surname>Gad</surname><given-names>A</given-names></name><name><surname>Alzamel</surname><given-names>FA</given-names></name></person-group>. <article-title>Outbreak of Bacille Calmette-Guerin-related lymphadenitis in Saudi children at a university hospital after a change in the strain of vaccine</article-title>. <source>Ann Saudi medicine</source>. (<year>2012</year>) <volume>32</volume>:<fpage>4</fpage>&#x02013;<lpage>8</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.5144/0256-4947.2012.4</pub-id>
</mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Al Jumaah</surname><given-names>S</given-names></name><name><surname>Al Hajjar</surname><given-names>S</given-names></name><name><surname>Al Mousa</surname><given-names>H</given-names></name></person-group>. <article-title>Bacille Calmette-Guerin vaccination in Saudi Arabia: benefits versus risks</article-title>. <source>Ann Saudi medicine</source>. (<year>2012</year>) <volume>32</volume>:<fpage>1</fpage>&#x02013;<lpage>3</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.5144/0256-4947.2012.1</pub-id>
</mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Cavazzana-Calvo</surname><given-names>M</given-names></name><name><surname>De Saint Basile</surname><given-names>G</given-names></name><name><surname>DeVillartay</surname><given-names>JP</given-names></name><name><surname>Di Santo</surname><given-names>JP</given-names></name><name><surname>Hivroz</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Naturally occurring primary deficiencies of the immune system</article-title>. <source>Annu Rev Immunol</source>. (<year>1997</year>) <volume>15</volume>:<fpage>93</fpage>&#x02013;<lpage>124</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1146/annurev.immunol.15.1.93</pub-id>
<pub-id pub-id-type="pmid">9143683</pub-id>
</mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal">
<article-title>Primary immunodeficiency diseases. Report of an IUIS Scientific Committee. International Union of Immunological Societies</article-title>. <source>Clin Exp Immunol</source>. (<year>1999</year>) <volume>118 Suppl 1</volume>:<fpage>1</fpage>&#x02013;<lpage>28</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1046/j.1365-2249.1999.00109.x</pub-id>
</mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tangye</surname><given-names>SG</given-names></name><name><surname>Al-Herz</surname><given-names>W</given-names></name><name><surname>Bousfiha</surname><given-names>A</given-names></name><name><surname>Cunningham-Rundles</surname><given-names>C</given-names></name><name><surname>Franco</surname><given-names>JL</given-names></name><name><surname>Holland</surname><given-names>SM</given-names></name><etal/></person-group>. <article-title>Human inborn errors of immunity: 2022 update on the classification from the international union of immunological societies expert committee</article-title>. <source>J Clin Immunol</source>. (<year>2022</year>) <volume>42</volume>:<page-range>1473&#x02013;507</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s10875-022-01289-3</pub-id>
</mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Notarangelo</surname><given-names>LD</given-names></name><name><surname>Neven</surname><given-names>B</given-names></name><name><surname>Cavazzana</surname><given-names>M</given-names></name><name><surname>Puck</surname><given-names>JM</given-names></name></person-group>. <article-title>Severe combined immunodeficiencies and related disorders</article-title>. <source>Nat Rev Dis Primers</source>. (<year>2015</year>) <volume>1</volume>:<fpage>15061</fpage>. doi:&#x000a0;0.1038/nrdp.2015.61
<pub-id pub-id-type="pmid">27189259</pub-id>
</mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marciano</surname><given-names>BE</given-names></name><name><surname>Huang</surname><given-names>CY</given-names></name><name><surname>Joshi</surname><given-names>G</given-names></name><name><surname>Rezaei</surname><given-names>N</given-names></name><name><surname>Carvalho</surname><given-names>BC</given-names></name><name><surname>Allwood</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies</article-title>. <source>J Allergy Clin Immunol</source>. (<year>2014</year>) <volume>133</volume>:<page-range>1134&#x02013;41</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jaci.2014.02.028</pub-id>
</mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Al-Odaib</surname><given-names>AN</given-names></name><name><surname>Abu-Amero</surname><given-names>KK</given-names></name><name><surname>Ozand</surname><given-names>PT</given-names></name><name><surname>Al-Hellani</surname><given-names>AM</given-names></name></person-group>. <article-title>A new era for preventive genetic programs in the Arabian Peninsula</article-title>. <source>Saudi Med J</source>. (<year>2003</year>) <volume>24</volume>:<page-range>1168&#x02013;75</page-range>.</mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Al-Mousa</surname><given-names>H</given-names></name><name><surname>Barbouche</surname><given-names>MR</given-names></name></person-group>. <article-title>Genetics of Inborn Errors of Immunity in highly consanguineous Middle Eastern and North African populations</article-title>. <source>Semin Immunol</source>. (<year>2023</year>) <volume>67</volume>:<fpage>101763</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.smim.2023.101763</pub-id>
<pub-id pub-id-type="pmid">37075586</pub-id>
</mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Al-Mousa</surname><given-names>H</given-names></name><name><surname>Al-Dakheel</surname><given-names>G</given-names></name><name><surname>Jabr</surname><given-names>A</given-names></name><name><surname>Elbadaoui</surname><given-names>F</given-names></name><name><surname>Abouelhoda</surname><given-names>M</given-names></name><name><surname>Baig</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>High incidence of severe combined immunodeficiency disease in Saudi Arabia detected through combined T cell receptor excision circle and next generation sequencing of newborn dried blood spots</article-title>. <source>Front Immunol</source>. (<year>2018</year>) <volume>9</volume>:<elocation-id>782</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2018.00782</pub-id>
<pub-id pub-id-type="pmid">29713328</pub-id>
</mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kwan</surname><given-names>A</given-names></name><name><surname>Abraham</surname><given-names>RS</given-names></name><name><surname>Currier</surname><given-names>R</given-names></name><name><surname>Brower</surname><given-names>A</given-names></name><name><surname>Andruszewski</surname><given-names>K</given-names></name><name><surname>Abbott</surname><given-names>JK</given-names></name><etal/></person-group>. <article-title>Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States</article-title>. <source>Jama</source>. (<year>2014</year>) <volume>312</volume>:<page-range>729&#x02013;38</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1001/jama.2014.9132</pub-id>
</mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Romanus</surname><given-names>V</given-names></name><name><surname>Fasth</surname><given-names>A</given-names></name><name><surname>Tordai</surname><given-names>P</given-names></name><name><surname>Wiholm</surname><given-names>BE</given-names></name></person-group>. <article-title>Adverse reactions in healthy and immunocompromised children under six years of age vaccinated with the Danish BCG vaccine, strain Copenhagen 1331: implications for the vaccination policy in Sweden</article-title>. <source>Acta paediatrica</source>. (<year>1993</year>) <volume>82</volume>:<page-range>1043&#x02013;52</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/j.1651-2227.1993.tb12808.x</pub-id>
</mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kagina</surname><given-names>BM</given-names></name><name><surname>Abel</surname><given-names>B</given-names></name><name><surname>Bowmaker</surname><given-names>M</given-names></name><name><surname>Scriba</surname><given-names>TJ</given-names></name><name><surname>Gelderbloem</surname><given-names>S</given-names></name><name><surname>Smit</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response</article-title>. <source>Vaccine</source>. (<year>2009</year>) <volume>27</volume>:<page-range>5488&#x02013;95</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.vaccine.2009.06.103</pub-id>
</mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shearer</surname><given-names>WT</given-names></name><name><surname>Dunn</surname><given-names>E</given-names></name><name><surname>Notarangelo</surname><given-names>LD</given-names></name><name><surname>Dvorak</surname><given-names>CC</given-names></name><name><surname>Puck</surname><given-names>JM</given-names></name><name><surname>Logan</surname><given-names>BR</given-names></name><etal/></person-group>. <article-title>Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience</article-title>. <source>J Allergy Clin Immunol</source>. (<year>2014</year>) <volume>133</volume>:<page-range>1092&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jaci.2013.09.044</pub-id>
</mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hesseling</surname><given-names>AC</given-names></name><name><surname>Rabie</surname><given-names>H</given-names></name><name><surname>Marais</surname><given-names>BJ</given-names></name><name><surname>Manders</surname><given-names>M</given-names></name><name><surname>Lips</surname><given-names>M</given-names></name><name><surname>Schaaf</surname><given-names>HS</given-names></name><etal/></person-group>. <article-title>Bacille Calmette-Guerin vaccine-induced disease in HIV-infected and HIV-uninfected children</article-title>. <source>Clin Infect Dis</source>. (<year>2006</year>) <volume>42</volume>:<page-range>548&#x02013;58</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1086/499953</pub-id>
</mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lotte</surname><given-names>A</given-names></name><name><surname>Wasz-Hockert</surname><given-names>O</given-names></name><name><surname>Poisson</surname><given-names>N</given-names></name><name><surname>Dumitrescu</surname><given-names>N</given-names></name><name><surname>Verron</surname><given-names>M</given-names></name><name><surname>Couvet</surname><given-names>E</given-names></name></person-group>. <article-title>BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics</article-title>. <source>Adv Tuberc Res</source>. (<year>1984</year>) <volume>21</volume>:<page-range>107&#x02013;93</page-range>.</mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>B</given-names></name><name><surname>Moreno</surname><given-names>S</given-names></name><name><surname>Burdach</surname><given-names>R</given-names></name><name><surname>Valenzuela</surname><given-names>MT</given-names></name><name><surname>Henriquez</surname><given-names>A</given-names></name><name><surname>Ramos</surname><given-names>MI</given-names></name><etal/></person-group>. <article-title>Clinical presentation of Bacillus Calmette-Guerin infections in patients with immunodeficiency syndromes</article-title>. <source>Pediatr Infect Dis J</source>. (<year>1989</year>) <volume>8</volume>:<page-range>201&#x02013;6</page-range>.</mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Botaro</surname><given-names>MH</given-names></name><name><surname>Maria</surname><given-names>ESJ</given-names></name><name><surname>Jamra</surname><given-names>SRA</given-names></name><name><surname>Geraldino</surname><given-names>SZ</given-names></name><name><surname>Roxo-Junior</surname><given-names>P</given-names></name></person-group>. <article-title>BCG vaccination in children with severe combined immunodeficiency in a tertiary center: evaluation of complications and risks</article-title>. <source>J Pediatr (Rio J)</source>. (<year>2024</year>) <volume>101</volume>(<issue>2</issue>):<page-range>224&#x02013;230</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jped.2024.09.008</pub-id>
</mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jafari</surname><given-names>L</given-names></name><name><surname>Hamidieh</surname><given-names>AA</given-names></name><name><surname>Behfar</surname><given-names>M</given-names></name><name><surname>Karamlou</surname><given-names>Y</given-names></name><name><surname>Shamsipour</surname><given-names>M</given-names></name><name><surname>Mohseni</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Effect of early bacillus calmette-guerin vaccination of pediatric severe combined immunodeficiency patients on the outcome of hematopoietic stem cell transplantation using a reduced-intensity conditioning regimen</article-title>. <source>Transplant Cell Ther</source>. (<year>2023</year>) <volume>29</volume>:<page-range>188.e1&#x02013;e8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jtct.2022.12.007</pub-id>
</mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cocchi</surname><given-names>N</given-names></name><name><surname>Jacobsen</surname><given-names>EM</given-names></name><name><surname>Hoenig</surname><given-names>M</given-names></name><name><surname>Schulz</surname><given-names>A</given-names></name><name><surname>Schuetz</surname><given-names>C</given-names></name></person-group>. <article-title>BCG disease in SCID: three decades of experience in a pediatric transplant center</article-title>. <source>J Clin Immunol</source>. (<year>2022</year>) <volume>42</volume>:<page-range>195&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s10875-021-01143-y</pub-id>
</mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Al-Saud</surname><given-names>B</given-names></name><name><surname>Al-Mousa</surname><given-names>H</given-names></name><name><surname>Al Gazlan</surname><given-names>S</given-names></name><name><surname>Al-Ghonaium</surname><given-names>A</given-names></name><name><surname>Arnaout</surname><given-names>R</given-names></name><name><surname>Al-Seraihy</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Primary immunodeficiency diseases in Saudi Arabia: a tertiary care hospital experience over a period of three years (2010-2013)</article-title>. <source>J Clin Immunol</source>. (<year>2015</year>) <volume>35</volume>:<page-range>651&#x02013;60</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s10875-015-0197-6</pub-id>
</mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Orange</surname><given-names>JS</given-names></name><name><surname>Ballas</surname><given-names>ZK</given-names></name></person-group>. <article-title>Natural killer cells in human health and disease</article-title>. <source>Clin Immunol</source>. (<year>2006</year>) <volume>118</volume>:<fpage>1</fpage>&#x02013;<lpage>10</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.clim.2005.10.011</pub-id>
<pub-id pub-id-type="pmid">16337194</pub-id>
</mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lai</surname><given-names>HC</given-names></name><name><surname>Chang</surname><given-names>CJ</given-names></name><name><surname>Lin</surname><given-names>CS</given-names></name><name><surname>Wu</surname><given-names>TR</given-names></name><name><surname>Hsu</surname><given-names>YJ</given-names></name><name><surname>Wu</surname><given-names>TS</given-names></name><etal/></person-group>. <article-title>NK cell-derived IFN-gamma protects against nontuberculous mycobacterial lung infection</article-title>. <source>J Immunol</source>. (<year>2018</year>) <volume>201</volume>:<page-range>1478&#x02013;90</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4049/jimmunol.1800123</pub-id>
</mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baris</surname><given-names>S</given-names></name><name><surname>Abolhassani</surname><given-names>H</given-names></name><name><surname>Massaad</surname><given-names>MJ</given-names></name><name><surname>Al-Nesf</surname><given-names>M</given-names></name><name><surname>Chavoshzadeh</surname><given-names>Z</given-names></name><name><surname>Keles</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>The middle east and north africa diagnosis and management guidelines for inborn errors of immunity</article-title>. <source>J Allergy Clin Immunol In practice</source>. (<year>2023</year>) <volume>11</volume>:<fpage>158</fpage>&#x02013;<lpage>80 e11</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jaip.2022.10.003</pub-id>
</mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Venkataraman</surname><given-names>A</given-names></name><name><surname>Yusuff</surname><given-names>M</given-names></name><name><surname>Liebeschuetz</surname><given-names>S</given-names></name><name><surname>Riddell</surname><given-names>A</given-names></name><name><surname>Prendergast</surname><given-names>AJ</given-names></name></person-group>. <article-title>Management and outcome of Bacille Calmette-Guerin vaccine adverse reactions</article-title>. <source>Vaccine</source>. (<year>2015</year>) <volume>33</volume>:<page-range>5470&#x02013;4</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.vaccine.2015.07.103</pub-id>
</mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Norouzi</surname><given-names>S</given-names></name><name><surname>Aghamohammadi</surname><given-names>A</given-names></name><name><surname>Mamishi</surname><given-names>S</given-names></name><name><surname>Rosenzweig</surname><given-names>SD</given-names></name><name><surname>Rezaei</surname><given-names>N</given-names></name></person-group>. <article-title>Bacillus Calmette-Guerin (BCG) complications associated with primary immunodeficiency diseases</article-title>. <source>J Infect</source>. (<year>2012</year>) <volume>64</volume>:<page-range>543&#x02013;54</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jinf.2012.03.012</pub-id>
</mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Al-Herz</surname><given-names>W</given-names></name><name><surname>Husain</surname><given-names>EH</given-names></name><name><surname>Adeli</surname><given-names>M</given-names></name><name><surname>Al Farsi</surname><given-names>T</given-names></name><name><surname>Al-Hammadi</surname><given-names>S</given-names></name><name><surname>Al Kuwaiti</surname><given-names>AA</given-names></name><etal/></person-group>. <article-title>BCG vaccine-associated complications in a large cohort of children with combined immunodeficiencies affecting cellular and humoral immunity</article-title>. <source>Pediatr Infect Dis J</source>. (<year>2022</year>) <volume>41</volume>:<page-range>933&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/INF.0000000000003678</pub-id>
</mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fekrvand</surname><given-names>S</given-names></name><name><surname>Yazdani</surname><given-names>R</given-names></name><name><surname>Olbrich</surname><given-names>P</given-names></name><name><surname>Gennery</surname><given-names>A</given-names></name><name><surname>Rosenzweig</surname><given-names>SD</given-names></name><name><surname>Condino-Neto</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Primary immunodeficiency diseases and bacillus calmette-guerin (BCG)-vaccine-derived complications: A systematic review</article-title>. <source>J Allergy Clin Immunol In practice</source>. (<year>2020</year>) <volume>8</volume>:<page-range>1371&#x02013;86</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jaip.2020.01.038</pub-id>
</mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Al Busaidi</surname><given-names>N</given-names></name><name><surname>Kp</surname><given-names>P</given-names></name><name><surname>Al-Jardani</surname><given-names>A</given-names></name><name><surname>Al-Sukaiti</surname><given-names>N</given-names></name><name><surname>Al Tamemi</surname><given-names>S</given-names></name><name><surname>Al-Rawahi</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>The spectrum of bacille calmette-guerin diseases in children-A decade of data from neonatal vaccination settings</article-title>. <source>Vaccines (Basel)</source>. (<year>2021</year>) <volume>9</volume>(<issue>2</issue>):<page-range>1&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/vaccines9020150</pub-id>
</mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shendi</surname><given-names>HM</given-names></name><name><surname>Al Kuwaiti</surname><given-names>AA</given-names></name><name><surname>Al Dhaheri</surname><given-names>AD</given-names></name><name><surname>Al-Hammadi</surname><given-names>S</given-names></name></person-group>. <article-title>The spectrum of inborn errors of immunity in the United Arab Emirates: 5 year experience in a tertiary center</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>837243</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.837243</pub-id>
<pub-id pub-id-type="pmid">35173743</pub-id>
</mixed-citation></ref></ref-list></back></article>